Christopher Smith

Christopher Smith

Former Director and Former Chief Executive OfficeratNeogenomics· In proxies 2021–2025

Pay in FY2025-64% from the year before · Neogenomics stock -28.6% the same year

Christopher Smith was paid $4.0M in FY2025 (Dec), down 64%. Neogenomics stock fell 28.6% that year.

Pay$100 in the stock at the end of FY20 → $22
Pay is from the Summary Compensation Table of each Neogenomics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NeogenomicsPublic company · 5 yr
    • Former Director and Former Chief Executive Officer2021 – Present · 5 yrStock in role -68%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?